Diagnostic utility of anti-cyclic citrullinated peptide antibodies in patients with early rheumatoid arthritis in the north of the country in Mexico. (159.18)

Abstract

Abstract Rheumatoid arthritis (RA) is a chronic systemic inflammatory disease which primarily causes a symmetric polyarthritis, which can progress into long-term disability. The diagnosis of RA combines the patient history of joint pain and stiffness, laboratory tests including biomarkers that can provide useful information to confirm the diagnosis of RA. To compare the diagnostic utility of biomarkers to confirm the diagnosis of RA, anticyclic citrullinated peptide (CCP) antibodies, rheumatoid factor (RF), erythrocyte sedimentation rate (ESR), and C-reactive protein (CRP) were tested in patients with early diagnosis RA. We work with 49 patients with RA all fulfilling the revised criteria of the ACR, and healthy volunteers. A commercial ELISA assay kit was used to test for anti-CCP antibodies; RF and CRP were measured by turbidimetric immunoassays; ESR was performed by Wintrobe assay. The levels of anti-CCP antibody titers, and FR were significantly higher in patients with early RA (54 % and 35% respectively) than in healthy controls (p <0.0001), however the 27% of patients were only positive to CCP test. No significant statistical correlation between anti-CCP antibody titers with inflammatory markers such as CRP or ESR was found. A positive predictive value was higher for anti-CCP antibodies in comparison to other markers.